CurrentBlue Cross Blue Shield - MassachusettsPolicy 920

Magnetic esophageal sphincter augmentation and selected endoscopic procedures for GERD

Defines medical necessity, investigational status, and prior authorization requirements for magnetic sphincter augmentation (LINX) and selected endoscopic procedures to treat gastroesophageal reflux disease (GERD) for commercial members.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyMagnetic esophageal sphincter augmentation and selected endoscopic procedures for GERD

Policy CodePolicy 920

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionSubmit prior authorization requests using Authorization Manager and complete Prior Authorization Request Form #956.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

MEDICALLY NECESSARYMSA status

INVESTIGATIONALStretta / bulking agents

Prior auth requiredAuthorization

Codes listedCovered CPTs

6–12 yrLong-term studies

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Magnetic esophageal sphincter augmentation (MSA) — Medically Necessary

Covered when ALL of the following are met:

MSA medical necessity criteria: Patient has a history of severe GERD for 2+ years with daily symptoms

From policy statements.

Objective evidence of reflux: Proven gastroesophageal reflux by endoscopy or ambulatory pH monitoring

Conservative therapy prerequisite: Tried and failed optimal non-surgical management including lifestyle modification, weight loss if indicated, and daily proton pump inhibitor use for >= 6 months

Prior authorization requires documentation of conservative therapy attempts.

Esophageal motor function: Evidence of adequate peristalsis by manometry or barium esophagram

Contraindications absent

Absolute contraindications (one or more): Morbid obesity (BMI >35); suspected or known allergy to metals such as iron, nickel, titanium, or stainless steel; scleroderma; Grade C or D (LA) esophagitis; esophageal stricture or gross esophageal anatomic abnormalities; prior esophageal or gastric surgery or endoscopic intervention; suspected or confirmed esophageal or gastric cancer
From policy contraindication list.

Transoral incisionless fundoplication (TIF) — Medically Necessary (partial criteria shown)

Covered when ALL of the following are met:

TIF medical necessity criteria (partial): Patient has a history of severe GERD for 2+ years with daily symptoms

Partial criteria from policy.

Objective evidence of reflux: Proven gastroesophageal reflux by endoscopy, ambulatory pH monitoring, or barium esophagram

Conservative therapy prerequisite: Tried and failed optimal non-surgical management of symptoms including lifestyle modification and daily PPI use

Hiatal hernia size: Hiatal hernia > 2 cm in axial height and > 2 cm in greatest transverse dimension> 2 cm

Transesophageal radiofrequency (Stretta) and endoscopic submucosal implantation/bulking agents — Investigational / Not Covered

Investigational procedures: Transesophageal radiofrequency to create submucosal thermal lesions of the gastroesophageal junction (Stretta) and endoscopic submucosal implantation or injection of prostheses or bulking agents (eg, polymethylmethacrylate beads, zirconium oxide spheres) are considered INVESTIGATIONAL as treatments for gastroesophageal reflux disease and are not covered.

Listed as investigational/not covered in policy.

Transesophageal radiofrequency treatment (commonly referred to as the Stretta procedure) and endoscopic submucosal implantation or injection of bulking agents are explicitly designated as investigational in this policy and are excluded from coverage for GERD. The policy language states these techniques create submucosal thermal lesions or place prostheses/bulking materials at the gastroesophageal junction and are considered investigational for the treatment of gastroesophageal reflux disease.

Where the policy or supporting references do not provide detailed exclusion language or operational guidance, the endnotes indicate that recommendations are based on expert opinion. In such cases, clinical judgment and the explicit investigational statements elsewhere in the policy should guide coverage decisions, and providers may be asked to supply additional documentation if the medical necessity of a procedure is unclear.

Procedures referenced among the investigational/excluded treatments may be billed using codes such as CPT 43201 (esophagoscopy with directed submucosal injection), CPT 43212 (esophagoscopy with placement of endoscopic stent), and CPT 43257 (EGD with delivery of thermal energy to the LES/gastric cardia, e.g., Stretta). These specific CPT descriptions are listed in the policy and align with the investigational designations in the coverage language.

Some reference and endnote sections do not include the explicit phrase 'not medically necessary' even though the policy classifies certain procedures as investigational. Where explicit 'not medically necessary' wording is absent, the policyʼs investigational designation and the listed exclusions should be interpreted as the basis for noncoverage; endnotes noting expert opinion signal that formal evidence-based recommendations may be limited.

Coding

Covered CPT Codes (when medical necessity met)CPTCovered

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed

ICD-10-PCS / Procedure CodesICD-10

ODV48ZZ

Restriction of Esophagogastric Junction, Via Natural or Artificial Opening Endoscopic

Investigational CPT CodesCPTNot Covered

43201	Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance
43212	Esophagoscopy, flexible, transoral; with placement of endoscopic stent
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia (eg, Stretta)

Provider Actions & Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for services described in this policy. Use Authorization Manager to submit initial authorization requests and the Complete Prior Authorization Request Form for Surgical and Transesophageal Endoscopic Procedures to Treat Gastroesophageal Reflux Disease (Form #956). For out-of-network providers, fax requests to 888-282-0780. Failure to obtain required precertification/preauthorization may result in denial of payment.

Authorization Manager (available 24/7) is the preferred submission method.
Complete Prior Authorization Request Form #956 must be used.
Out-of-network fax: 888-282-0780.

Documentation Required

Guideline & Documentation Expectations

The policy references clinical society guidance (SAGES, NICE, American Foregut Society) and FDA materials. These references imply expectations for documented patient selection and justification consistent with guideline recommendations (eg, documentation of proven GERD, prior conservative therapy, testing results such as endoscopy, pH monitoring, and manometry). Ensure charts and submitted documentation explicitly address the clinical criteria cited in the policy and society guidance.

Background

Gastroesophageal reflux disease (GERD) is the reflux of stomach acid into the esophagus leading to symptoms and/or mucosal injury across a spectrum of severity. Clinical presentation ranges from intermittent heartburn responsive to lifestyle measures and acid suppression to persistent, daily symptoms or complications (for example, esophagitis or Barrett mucosa) that may not be controlled with medical therapy. For patients with chronic or severe disease who have failed optimal non‑surgical management, surgical and device-based options — including fundoplication and magnetic sphincter augmentation — are considered in the appropriate clinical context.

Definitions

Magnetic sphincter augmentation (MSA / LINX) — short definition and device description

DefinitionA laparoscopically implanted ring of interlinked titanium beads with magnetic cores placed around the esophagus at the gastroesophageal junction to augment the lower esophageal sphincter and reduce reflux.

Mechanism of actionMagnetic attraction between beads augments the lower esophageal sphincter to prevent gastric reflux while allowing the beads to separate during swallowing so the esophagus is not compressed.

PlacementPlaced around the esophagus at the level of the gastroesophageal junction using standard laparoscopic techniques.

Intended populationIndividuals with GERD symptoms despite maximum medical therapy (eg, proton pump inhibitors) who seek an alternative to more invasive surgery.

Removability and safety considerationsDevice can be removed laparoscopically if severe adverse events occur or if magnetic resonance imaging is needed; potential adverse events include dysphagia or odynophagia.